Canntab Therapeutics (CSE:PILL) (“Canntab” or the “Company”) is a company with a clear vision of becoming the leader in solid oral dosage formulation of cannabis.  Their unique products offer advantages to the medical community, patients, adult use consumers and governments.  Canntab is pleased to provide this corporate update to its shareholders.

This includes;


  • An excellent capitalized structure of approximately 28.6M shares outstanding on a fully diluted basis with no need for short term financing of its business plan.
  • A strong intellectual property portfolio with 13 patents pending in the United States and Canada pertaining to the formulation of tablets including instant release, extended release, flash melt and bi-layered. The products will be available in 2.5g, 5g and 10g tablets.
  • An application to become a Licensed Producer (Non Grower) under the Access to Cannabis for Medical Purposes Regulations and has confirmation from Health Canada that its application had been received.
  • A notice that it is now a part of the Composite Index of the Canadian Securities Exchange as part of their quarterly rebalancing.
  • Reaching a milestone in its development of a patent-pending oral extended release formulation for cannabinoids in collaboration with Emblem Corp. (TSXV: EMC, OTCQX: EMMBF). Dissolution testing indicated that the Extended Release Tablets released cannabinoids consistently over a 12-hour period. Given these positive test results, Canntab is manufacturing pivotal batches of these tablets for further clinical testing. This will lead to the filing of dossiers with regulatory agencies around the world for approval of Canntab’s unique solid oral dose delivery systems.
  • Health Canada’s approval of Canntab’s ‘420 Therapeutics’ brand of Cannabis wellness products. These capsules are made with purified organic hemp seed oil and are an easy and convenient way to enjoy the health benefits of hemp oil. This is an important milestone achievement for Canntab in their move towards manufacturing full spectrum hemp derived CBD.
  • Announcement of the signing of a non-binding Letter of Intent with NewCanna S.A.S of Bogota, Colombia for the establishment of a significant bi-lateral relationship covering the sale and distribution of Canntab’s products in Colombia, Chile, Paraguay and Spain with a one-time, non-refundable license fee ($2 million US) payable to Canntab by NewCanna.
  • Announcement of the signing of a non-binding Letter of Intent with Labsco Promedic SA for the establishment of a joint venture relationship covering, on an exclusive basis, the sales and distribution of Canntab products in Mexico.

Jeff Renwick, CEO of Canntab Therapeutics Ltd., says, “In our short history on the public markets, Canntab has already reached a number of significant milestones. Canntab is leveraging its first mover advantage and developing an important IP portfolio to actively pursue other high-level discussions for partnerships with industry leaders. CBD and THC in tablet form is an important category with few worldwide players at this time and Canntab believes that it is well positioned to build significant shareholder value by aggressively pursuing these opportunities.”

About Canntab

Canntab Therapeutics Limited is a Canadian cannabis oral dosage formulation company based in Markham Ontario, engaged in the research and development of advanced pharmaceutical grade formulations of cannabinoids. Canntab has developed patented technology to deliver standardized medical cannabis extract from selective strains in a variety of extended/sustained release pharmaceutical dosages for therapeutic use. In doing so, Canntab has developed a suite of precision oral dose products that are unavailable elsewhere in the marketplace.  Canntab’s primary focus is on providing cannabis-based products to medical professionals that can be used to deliver therapeutic treatments to their patients.

FOR ADDITIONAL INFORMATION, PLEASE CONTACT:

Canntab Therapeutics Limited
Richard Goldstein, CFO
Office: 416 957-6303
Email: info@canntab.ca

Certain statements included in this press release constitute forward-looking information or statements (collectively, “forward-looking statements”), including those identified by the expressions “anticipate”, “believe”, “plan”, “estimate”, “expect”, “intend”, “may”, “should” and similar expressions to the extent they relate to the Company or its management. The forward-looking statements are not historical facts but reflect current expectations regarding future results or events. This press release contains forward looking statements. These forward-looking statements are based on current expectations and various estimates, factors and assumptions and involve known and unknown risks, uncertainties and other factors. Although management of the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking statements or forward-looking information, there may be other factors that cause results not to be anticipated, estimated, or intended.

Neither the Canadian Securities Exchange (the “CSE”) nor its Regulation Services Provider (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this release.

Click here to connect with Canntab Therapeutics (CSE:PILL) for an Investor Presentation. 

Source: globenewswire.ca

Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW)(CSE:LXX) (the “Company” or “Lexaria”), a global innovator in drug delivery platforms, is pleased to announce the appointment of Mr. Al Reese, Jr., to its Board of Directors

Mr. Reese has over 40 years experience in public and private businesses including as CFO of a formerly Nasdaq-listed energy company where he arranged finance transactions totaling over $10 billion dollars during his 20-year tenure. Mr. Reese was a Director and Chairman of the Audit Committee of a community bank in Texas for ten years until such time as it was acquired by a larger banking group in 2018.

Keep reading... Show less

Mexico looks to be closer than ever to cannabis reform, with the country releasing its regulation plans to make the drug legal in medical settings.

Meanwhile, despite the financial hardships seen recently in the Canadian cannabis market, CEOs in the country are still receiving top dollar, as per a new study.

Keep reading... Show less

Not for Distribution to United States Newswire Services or for Dissemination in the United States

Cresco Labs (CSE:CL) (OTCQX:CRLBF) (“Cresco” or the “Company”), one of the largest vertically integrated multistate cannabis operators in the United States, announced today the pricing of its previously announced best efforts overnight marketed offering (the “Offering”) of subordinate voting shares (the “Offered Securities”) of the Company at a price of C$16.00 per share for a total gross proceeds of approximately US$125 Million. The issue price represents a 3.3% discount to the last close of the Company’s subordinate voting shares traded on the Canadian Securities Exchange as of January 14, 2021. 100% of the Offering is expected to be purchased by a total of seven new and existing institutional investors, including current shareholder, Wasatch Global Investors.

Keep reading... Show less

Wall Street Reporter, the trusted name in financial news since 1843, has published reports on the latest comments and insights from leaders at: Tilray, Inc. (NASDAQ: TLRY), Icanic Brands (OTC: ICNAF) (CSE: ICAN) Red Light Holland (OTC: TRUFF) (CSE: TRIP) and Aphria, Inc. (NASDAQ: APHA).

Investors are cheering new and expected legislation which is opening new market opportunities for both cannabis and psychedelics globally. Innovation in premium branding, growing technologies, manufacturing, with operational execution are key, in the drive towards profitability. Wall Street Reporter highlights the latest comments from industry thought leaders in cannabis and psychedelics:

Keep reading... Show less

Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW)(CSE:LXX) (the “Company”) today announced the closing of its previously announced underwritten public offering (the “Offering”) of 1,828,571 units, each unit consisting of one share of common stock and one warrant to purchase one share of common stock at a public offering price of $5.25 per unit (all prices in US$). The warrants have an exercise price of $6.58 per share, are immediately exercisable and will expire five years following the date of issuance. In connection with the Offering, the underwriter exercised in full its option to purchase an additional 274,285 shares of common stock and additional warrants to purchase 274,285 shares of common stock. The gross proceeds from the Offering were approximately $11.04 million, before deducting underwriting discounts and estimated offering expenses. No securities were offered or sold in Canada, including through the CSE or any other trading market in Canada

H.C. Wainwright & Co. (“Wainwright”) acted as the sole book-running manager for the Offering and is a non-related party to the Company.

Keep reading... Show less